OMERS ADMINISTRATION Corp bought a new position in Drugs Made In America Acquisition II Corp. (NASDAQ:DMII – Free Report) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 1,000,000 shares of the company’s stock, valued at approximately $9,900,000.
Several other large investors have also recently made changes to their positions in the company. Glazer Capital LLC bought a new stake in shares of Drugs Made In America Acquisition II in the fourth quarter worth about $23,264,000. First Trust Capital Management L.P. bought a new stake in shares of Drugs Made In America Acquisition II in the fourth quarter worth about $20,474,000. Hudson Bay Capital Management LP bought a new stake in shares of Drugs Made In America Acquisition II in the fourth quarter worth about $19,493,000. Wolverine Asset Management LLC bought a new stake in shares of Drugs Made In America Acquisition II in the fourth quarter worth about $10,521,000. Finally, Picton Mahoney Asset Management bought a new stake in shares of Drugs Made In America Acquisition II in the fourth quarter worth about $8,662,000.
Analyst Upgrades and Downgrades
Several equities research analysts have weighed in on DMII shares. Wall Street Zen raised Drugs Made In America Acquisition II from a “sell” rating to a “hold” rating in a research note on Sunday, May 10th. Weiss Ratings raised Drugs Made In America Acquisition II from a “sell (e)” rating to a “sell (e+)” rating in a research note on Thursday. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has a consensus rating of “Sell”.
Drugs Made In America Acquisition II Trading Up 0.0%
DMII opened at $10.09 on Tuesday. The company’s 50 day simple moving average is $10.03. Drugs Made In America Acquisition II Corp. has a one year low of $9.86 and a one year high of $10.09.
Drugs Made In America Acquisition II Profile
Drugs Made In America Acquisition II (NASDAQ:DMII) is a special purpose acquisition company (SPAC) formed to raise capital through a public listing for the purpose of effecting a business combination. As a blank‑check vehicle, the company itself does not operate a traditional commercial business; instead, it seeks to identify, negotiate and complete an acquisition, merger, share exchange, asset purchase or similar business transaction with one or more target companies.
The stated investment focus reflected in the company’s name indicates an emphasis on the pharmaceutical and life sciences sector, with a particular interest in domestic drug manufacturing, supply‑chain resiliency and related healthcare operations in the United States.
Read More
- Five stocks we like better than Drugs Made In America Acquisition II
- These 5 Companies Just Made a Massive Bet on Themselves
- 5 Stocks Built to Thrive in a Higher-for-Longer Economy
- RH’s Strong Q1 Still Leaves Investors With One Big Question
- Iran Ceasefire or Not, These 3 Companies Could Win
Want to see what other hedge funds are holding DMII? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Drugs Made In America Acquisition II Corp. (NASDAQ:DMII – Free Report).
Receive News & Ratings for Drugs Made In America Acquisition II Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Drugs Made In America Acquisition II and related companies with MarketBeat.com's FREE daily email newsletter.
